23 results on '"Tambas, Makbule"'
Search Results
2. Computed Tomography–Guided Optimization of Needle Insertion for Combined Intracavitary/Interstitial Brachytherapy With Utrecht Applicator in Locally Advanced Cervical Cancer
- Author
-
Tambas, Makbule, Tavli, Busra, Bilici, Nazli, Dizman, Aysen, Sertel, Huseyin, and Fayda, Merdan
- Published
- 2021
- Full Text
- View/download PDF
3. The expression level of fibulin-2 in the circulating RNA (ctRNA) of epithelial tumor cells of peripheral blood and tumor tissue of patients with metastatic lung cancer
- Author
-
Avsar, Mukaddes, Tambas, Makbule, Yalniz, Zubeyde, Akdeniz, Demet, Tuncer, Seref Bugra, Kilic, Seda, Sukruoglu Erdogan, Ozge, Ciftci, Rumeysa, Dagoglu, Nergiz, Vatansever, Sezai, and Yazici, Hulya
- Published
- 2019
- Full Text
- View/download PDF
4. Conventionally Fractionationed Volumetric Arc Therapy versus Hypofractionated Stereotactic Body Radiotherapy: Quality of Life, Side Effects, and Prostate-Specific Antigen Kinetics in Localized Prostate Cancer
- Author
-
Tambas, Makbule, Agaoglu, Fulya, Iribas, Ayca, Guveli, Murat, Dizdar, Yavuz, Okutan, Murat, Sahin, Dilek, Tenekeci, Nuri, and Darendeliler, Emin
- Published
- 2016
- Full Text
- View/download PDF
5. Patient selection for proton therapy in head and neck cancer
- Author
-
Tambas, Makbule, Langendijk, Johannes Albertus, Steenbakkers, Roel, and van der Laan, Hans Paul
- Abstract
This thesis has thoroughly investigated the criteria used in Europe to select patients for proton therapy. Head and neck cancer was found to be the second most commonly treated tumor type after tumors in the central nervous system, accounting for 15% of all adult patients receiving proton therapy in Europe in 2020. It has shown that model-based selection of head and neck cancer patients for proton therapy is clinically feasible. It describes developed preselection and decision support tools to identify patients who may benefit most from proton therapy. In addition, an extensive systematic review of the models that can be used to estimate the risk of radiation-induced complications after radiotherapy in head and neck cancer patients was performed.
- Published
- 2023
6. Effect of the childhood trauma on the adjustment to cancer in the patients with breast cancer
- Author
-
Guveli, Hulya, Guveli, Murat Emin, Sen, Fatma, Oflaz, Serap, Gurdal, Necla, Tambas, Makbule, Kucucuk, Seden, Aydıner, Adnan, and Ozkan, Mine
- Published
- 2017
- Full Text
- View/download PDF
7. Radiosurgery effects and adverse effects in symptomatic eloquent brain-located Cavernomas.
- Author
-
Berber, Tanju, Celik, Suat Erol, Aksaray, Ferdi, Yoney, Adnan, Harmanci, Kemal, Tambas, Makbule, Yılmaz, Binnur Dönmez, Numanoglu, Cakir, Yolcu, Ahmet, Açan, Hilal İrem, Dinçer, Selvi Tabak, and Yıldırım, Berna Akkuş
- Subjects
RADIOSURGERY ,STEREOTACTIC radiosurgery ,PEOPLE with epilepsy ,LEVETIRACETAM ,VAGUS nerve - Abstract
In this study, the dose schedule efficacy, safety and late adverse effects of stereotactic radiosurgery (SRS) were evaluated for patients with symptomatic cavernomas who were not eligible for surgery and treated with SRS. Between January 2013 and December 2018, 53 patients with cavernomas were treated using SRS with the CyberKnife® system. Patients' diseases were deeply located or were in subcortical functional brain regions. In addition to bleeding, 23 (43.4%) patients had epilepsy, 12 (22.6%) had neurologic symptoms and 16 patients (30.2%) had severe headaches. The median volume was 741 (range, 421–1351) mm
3 , and the median dose was 15 (range, 14–16) Gy in one fraction. After treatment, six (50%) of 12 patients with neurologic deficits still had deficits. Rebleeding after treatment developed in only two (3.8%) patients. The drug was completely stopped in 14 (60.9%) out of 23 patients who received epilepsy treatment, and the dose of levetiracetam decreased from 2000 mg to 1000 mg in four (17.3%) of nine patients. Radiologically, complete response (CR) was observed in 13 (24.5%) patients, and partial responses (PR) were observed in 32 (60.2%) patients. Clinical response of CR was observed in 30 (56.6%) patients, PR was observed in 16 (30.2%), stable disease (SD) was observed in three (5.7%) and four (7.5%) patients progressed. In conclusion, SRS applied in the appropriate dose schedule may be an effective and reliable method in terms of symptom control and prevention of rebleeding, especially in patients with inoperable cavernomas. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
8. Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma
- Author
-
Sen, Fatma, Yildiz, Ibrahim, Odabas, Hatice, Tambas, Makbule, Kilic, Leyla, Karadeniz, Ahmet, Altun, Musa, Ekenel, Meltem, Serilmez, Murat, Duranyildiz, Derya, Bavbek, Sevil, and Basaran, Mert
- Published
- 2015
- Full Text
- View/download PDF
9. The efficacy of Pistacia Terebinthus soap in the treatment of cetuximab-induced skin toxicity
- Author
-
Tastekin, Didem, Tambas, Makbule, Kilic, Kemal, Erturk, Kayhan, and Arslan, Deniz
- Published
- 2014
- Full Text
- View/download PDF
10. Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients
- Author
-
Tastekin, Didem, Kargin, Suleyman, Karabulut, Mehmet, Yaldız, Naile, Tambas, Makbule, Gurdal, Necla, Tatli, Ali Murat, Arslan, Deniz, Gok, Ali Fuat Kaan, and Aykan, Faruk
- Published
- 2014
- Full Text
- View/download PDF
11. Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
- Author
-
Sen, Fatma, Tambas, Makbule, Ozkaya, Kubra, Guveli, Murat Emin, Ciftci, Rumeysa, Ozkan, Berker, Oral, Ethem Nezih, Saglam, Esra Kaytan, Saip, Pinar, Toker, Alper, Demir, Adalet, Firat, Pinar, Aydiner, Adnan, and Eralp, Yesim
- Published
- 2016
- Full Text
- View/download PDF
12. Current practice in proton therapy delivery in adult cancer patients across Europe.
- Author
-
Tambas, Makbule, van der Laan, Hans Paul, Steenbakkers, Roel J.H.M., Doyen, Jerome, Timmermann, Beate, Orlandi, Ester, Hoyer, Morten, Haustermans, Karin, Georg, Petra, Burnet, Neil G, Gregoire, Vincent, Calugaru, Valentin, Troost, Esther G.C., Hoebers, Frank, Calvo, Felipe A., Widder, Joachim, Eberle, Fabian, van Vulpen, Marco, Maingon, Philippe, and Skóra, Tomasz
- Subjects
- *
CANCER patients , *PROTON therapy , *HEAD & neck cancer , *NATIONAL health services , *PATIENT selection - Abstract
• In total, more than 4000 adult patients are currently treated with PT across Europe annually. • CNS and HNC tumours are the most frequently treated tumour sites. • Most centres use national or institutional guidelines for selecting patients for PT. • Treatments are usually reimbursed by national health care systems. • Most patients are included in prospective data registries and clinical trials. Major differences exist among proton therapy (PT) centres regarding PT delivery in adult cancer patient. To obtain insight into current practice in Europe, we performed a survey among European PT centres. We designed electronic questionnaires for eight tumour sites, focusing on four main topics: 1) indications and patient selection methods; 2) reimbursement; 3) on-going or planned studies, 4) annual number of patients treated with PT. Of 22 centres, 19 (86%) responded. In total, 4233 adult patients are currently treated across Europe annually, of which 46% consists of patients with central nervous system tumours (CNS), 15% head and neck cancer (HNC), 15% prostate, 9% breast, 5% lung, 5% gastrointestinal, 4% lymphoma, 0.3% gynaecological cancers. CNS are treated in all participating centres (n = 19) using PT, HNC in 16 centres, lymphoma in 10 centres, gastrointestinal in 10 centres, breast in 7 centres, prostate in 6 centres, lung in 6 centres, and gynaecological cancers in 3 centres. Reimbursement is provided by national health care systems for the majority of commonly treated tumour sites. Approximately 74% of centres enrol patients for prospective data registration programs. Phase II-III trials are less frequent, due to reimbursement and funding problems. Reasons for not treating certain tumour types with PT are lack of evidence (30%), reimbursement issues (29%) and/or technical limitations (20%). Across European PT centres, CNS tumours and HNC are the most frequently treated tumour types. Most centres use indication protocols. Lack of evidence for PT and reimbursement issues are the most reported reasons for not treating specific tumour types with PT. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Mapping the Future of Particle Radiobiology in Europe: The INSPIRE Project
- Author
-
Henthorn, Nicholas T., Sokol, Olga, Durante, Marco, De Marzi, Ludovic, Pouzoulet, Frederic, Miszczyk, Justyna, Olko, Pawel, Brandenburg, Sytze, van Goethem, Marc Jan, Barazzuol, Lara, Tambas, Makbule, Langendijk, Johannes A., Vondráĉek, Vladimír, Bodenstein, Elisabeth, Pawelke, Jörg, Lomax, Antony J., Weber, Damien C., Dasu, Alexandru, Stenerlöw, Bo, Poulsen, Per R., Sørensen, Brita S., Grau, Cai, Sitarz, Mateusz K., Heuskin, Anne-Catherine, Lucas, Stephane, Warmenhoven, John W., Merchant, Michael J., Mackay, Ran I., and Kirkby, Karen J.
- Subjects
Beamline ,Radiotherapy ,Radiobiology ,Proton therapy ,Irradiation - Abstract
Particle therapy is a growing cancer treatment modality worldwide. However, there still remains a number of unanswered questions considering differences in the biological response between particles and photons. These questions, and probing of biological mechanisms in general, necessitate experimental investigation. The “Infrastructure in Proton International Research” (INSPIRE) project was created to provide an infrastructure for European research, unify research efforts on the topic of proton and ion therapy across Europe, and to facilitate the sharing of information and resources. This work highlights the radiobiological capabilities of the INSPIRE partners, providing details of physics (available particle types and energies), biology (sample preparation and post-irradiation analysis), and researcher access (the process of applying for beam time). The collection of information reported here is designed to provide researchers both in Europe and worldwide with the tools required to select the optimal center for their research needs. We also highlight areas of redundancy in capabilities and suggest areas for future investment., Frontiers in Physics, 8, ISSN:2296-424X
- Published
- 2020
14. First experience with model-based selection of head and neck cancer patients for proton therapy.
- Author
-
Tambas, Makbule, Steenbakkers, Roel J.H.M., van der Laan, Hans P., Wolters, Atje M., Kierkels, Roel G.J., Scandurra, Dan, Korevaar, Erik W., Oldehinkel, Edwin, van Zon-Meijer, Tineke W.H., Both, Stefan, van den Hoek, Johanna G.M., and Langendijk, Johannes A.
- Subjects
- *
PROTON therapy , *CANCER patients , *HEAD & neck cancer , *HYPOPHARYNGEAL cancer , *PATIENT selection - Abstract
• Model-based selection of patients with HNC for proton is clinically feasible. • Around 35% of HNC patients qualify for protons. • Most patients are selected based on ΔNTCP in dysphagia-related models. • Patients with advanced and pharyngeal tumor have higher probability to be selected. In the Netherlands, head and neck cancer (HNC) patients qualify for intensity modulated proton therapy (IMPT) based on model-based selection (MBS). The aim of this study was to evaluate the first experience in MBS of HNC patients. Patients who were subjected to MBS (Jan 2018–Sep 2019) were evaluated. A VMAT plan was created for all patients with optimal sparing of organ at risks (OARs) in normal tissue complication probability (NTCP) models for a number of toxicities. An IMPT plan was created only for those with NTCP difference (ΔNTCP) between VMAT and best-case scenario for proton (assuming 0 Gy dose for all OARs in IMPT plan) that exceeded any ΔNTCP-thresholds defined in Dutch National Indication Protocol. These patients qualified for a robust IMPT-plan creation with similar target doses and subsequent plan comparison. Of 227 patients, 141 (62%) qualified for plan comparison, of which 80 (35%) were eventually selected for proton therapy. Most patients were selected based on the ΔNTCP for dysphagia-related toxicities. The selection rate was higher among patients with advanced disease, pharyngeal tumors, and/or baseline complaints. A significant reduction in all OAR doses and NTCP values was obtained with IMPT compared with VMAT in both selected and non-selected patients, but more pronounced in patients selected for protons. Model-based selection of patients with HNC for proton therapy is clinically feasible. Approximately one third of HNC patients qualify for protons and these patients have the highest probability to benefit from protons in terms of toxicity prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. SERUM OMENTIN, VISFATIN, VASPIN ARE NOT USEFULL DIAGNOSTIC BIOMARKERS IN COLORECTAL CANCER
- Author
-
Şen, Fatma, Erdemli, Hacı Kemal, Bademler, Suleyman, Ilhan, Mehmet, Yavuzer, Hakan, Tambas, Makbule, Salıs, Osman, Kocabas, Ramazan, and Bedir, Abdulkerim
- Abstract
Gastrointestinal carcinomas are more prevalent in obese populations compared to nonobese ones. Based on complex interplay between adipokines, obesity is also characterized by increased oxidative stress. Over-expression of oxidative stress damages cellular structures together with under-production of anti-oxidant mechanisms, leading to development of obesity-related complications. It was found both primary and metastatic carcinomas and may be critical in regulation of the oxidative status of cancer cells. This study investigated the omentin, visfatin and vaspin levels in patients with colorectal carcinomas (CRC).Total of 60 patients with CRC (male/female:25/35) and 30 controls (male/female:15/15) were enrolled. Results were given as median (%95 Cl). Mann-Whitney test was used for the comparison of groups.Serum omentin level was 32.2 (0.3-217.3) ng/L in CRC patients and 34.9 (11.3-123.4) ng/L in control group (P>0.05). Serum visfatin level was 6.8 (2.6-31.9) ng/mL in CRC patients and 9.2 (4.3-26.3) ng/L in controls (P>0.05). Serum vaspin level was 0.7 (0.4-7.6) ng/ml and 1.1 (0.6-4.2) ng/ml in CRC patients and control group, respectively (P>0.05). Serum omentin, visfatin and vaspin levels of CRC patients were not different than those of control group. Thus, serum omentin, visfatin and vaspin levels should not be used as a diagnostic biomarker of CRC., Journal of International Society of Antioxidants in Nutrition & Health, Vol 3, No 3 (2016)
- Published
- 2016
- Full Text
- View/download PDF
16. Human Papillomavirus in Head and Neck Cancer
- Author
-
Tambas, Makbule
- Subjects
Medical / Diseases - Abstract
Throughout the last three decades, there has been a notable shift in the epidemiology of head and neck cancer (HNC) worldwide. A rapidly spreading subtype of HNCs is caused by human papillomavirus (HPV) infection. HPV-related cancers are now considered to constitute 30–65% of all HNC cases and 50–80% of oropharyngeal cancers. HPV-positive oropharyngeal cancers have a unique demographic profile and tumor biology characteristics. HPV-associated patients predominantly consist of younger men with better performance status and fewer comorbid diseases. They have better dentition, higher numbers of oral sex partners, and use less amount of tobacco or alcohol, higher amount of marijuana compared with HPV-negative patients. In addition, patients with HPV-positive tumors have a 60–80% reduced mortality rates, a finding that was confirmed by multiple trials and led to several ongoing deintensification studies. This chapter describes epidemiologic features of HPV-positive HNC, risk factors for HPV infection and HPV-associated oropharyngeal cancer, HPV detection methods, mechanisms of carcinogenesis and improved treatment response, and the impact of HPV status on clinical outcome as well as deintensification approaches and potential of vaccination.
- Published
- 2016
17. Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer
- Author
-
Aydiner, Adnan, Sen, Fatma, Tambas, Makbule, Ciftci, Rumeysa, Eralp, Yesim, Saip, Pinar, Karanlik, Hasan, Fayda, Merdan, Kucucuk, Seden, Onder, Semen, Yavuz, Ekrem, Muslumanoglu, Mahmut, and Igci, Abdullah
- Subjects
Adult ,Bridged-Ring Compounds ,Turkey ,Incidence ,Carcinoma, Ductal, Breast ,Observational Study ,Antineoplastic Agents ,Triple Negative Breast Neoplasms ,Middle Aged ,Prognosis ,Disease-Free Survival ,Humans ,Female ,Neoplasm Invasiveness ,Taxoids ,Neoplasm Recurrence, Local ,Mastectomy ,Research Article ,Neoplasm Staging ,Retrospective Studies - Abstract
Metaplastic breast carcinoma (MBC) differs from classic invasive ductal carcinomas regarding incidence, pathogenesis, and prognosis. The purpose of this study was to compare patients with MBC with clinicopathologic and treatment-matched patients with triple-negative breast carcinoma (TNBC) in terms of response to treatment, progression, and survival. Fifty-four patients with MBC and 51 with TNBC, who were treated at Istanbul University, Institute of Oncology, between 1993 and 2014, were included in the study. After correctly matching the patients with 1 of the 2 groups, they were compared to determine differences in response to treatment, disease progression, clinical course, and survival. At a median follow-up of 28 months, 18 patients (17.1%) died and 27 (25.5%) had disease progression. Metaplastic histology was significantly correlated with worse 3-year progression-free survival (PFS) (51 ± 9% vs. 82 ± 6%, P = 0.013) and overall survival (OS) (68 ± 8% vs. 94 ± 4%, P = 0.009) compared with TNBC histology. Patients who received taxane-based chemotherapy (CT) regimens or adjuvant radiotherapy had significantly better PFS (P = 0.002 and P
- Published
- 2015
18. Do circulating long non-coding RNAs (lncRNAs) (LincRNA-p21, GAS 5, HOTAIR) predict the treatment response in patients with head and neck cancer treated with chemoradiotherapy?
- Author
-
Fayda, Merdan, Isin, Mustafa, Tambas, Makbule, Guveli, Murat, Meral, Rasim, Altun, Musa, Sahin, Dilek, Ozkan, Gozde, Sanli, Yasemin, Isin, Husniye, Ozgur, Emre, and Gezer, Ugur
- Abstract
Long non-coding RNAs (lncRNAs) have been shown to be aberrantly expressed in head and neck cancer (HNC). The aim of the present study was to evaluate plasma levels of three lncRNA molecules (lincRNA-p21, GAS5, and HOTAIR) in the treatment response in HNC patients treated with radical chemoradiotherapy (CRT). Forty-one patients with HNC were enrolled in the study. Most of the patients had nasopharyngeal carcinoma ( n = 27, 65.9 %) and locally advanced disease. Blood was drawn at baseline and treatment evaluation 4.5 months after therapy. lncRNAs in plasma were measured by semiquantitative PCR. Treatment response was evaluated according to clinical examination, RECIST and PERCIST criteria based on magnetic resonance imaging (MRI), and positron emission tomography with computed tomography (PET/CT) findings. Complete response (CR) rates were 73.2, 36.6, and 50 % for clinical investigation, PET/CT-, or MRI-based response evaluation, respectively. Predictive value of lncRNAs was investigated in patients with CR vs. those with partial response (PR)/progressive disease (PD). We found that post-treatment GAS5 levels in patients with PR/PD were significantly higher compared with patients with CR based on clinical investigation ( p = 0.01). Receiver operator characteristic (ROC) analysis showed that at a cutoff value of 0.3 of GAS5, sensitivity and specificity for clinical tumor response were 82 and 77 %, respectively. Interestingly, pretreatment GAS5 levels were significantly increased in patients with PR/PD compared to those with CR upon MRI-based response evaluation ( p = 0.042). In contrast to GAS5, pretreatment or post-treatment lincRNA-p21 and HOTAIR levels were not informative for treatment response. Our results suggest that circulating GAS5 could be a biomarker in predicting treatment response in HNC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
19. Factors affecting progression-free survival in non-HIV-related Kaposi sarcoma.
- Author
-
Sen, Fatma, Tambas, Makbule, Ciftci, Rumeysa, Toz, Bahtiyar, Kilic, Leyla, Bozbey, Hamza U., Karanlik, Hasan, Kurul, Sidika, Vatansever, Sezai, Oral, Ethem N., Saglam, Esra K., Kizir, Ahmet, Saip, Pinar, and Aydiner, Adnan
- Subjects
- *
KAPOSI'S sarcoma , *PROGRESSION-free survival , *CANCER radiotherapy , *IMMUNOSUPPRESSION , *HYPERTENSION , *THERAPEUTICS - Abstract
Background: Non-HIV related Kaposi sarcoma (NHKS) is a rare indolent neoplasm which is more common around Mediterranean origin. Data concerning factors that influence progression-free survival (PFS) for NHKS are insufficient. The purpose of present retrospective analysis was to distinguish the factors affecting PFS in patients with NHKS.Methods: A hundred and twenty-eight consecutive patients with NHKS who were treated or observed between 1997 and 2014 at Istanbul University Institute of Oncology were included into the study. Treatment response and progression definitions were determined according to different treatment modalities administered at first line.Results: Majority of patients were male (n = 97, 75.8%). Median age of the whole group was 66 years (28–85). Of the patients, 15 patients were immunosuppressant, whereas 113 patients had no disease that caused immunosuppression. Patients were treated with local excision (n = 57, 44.5%), chemotherapy (n = 32, 25.0%) and/or radiotherapy (n = 13, 10.2%) or observed without treatment (n = 26, 20.3%). At a median follow-up of 28 months, 71 (55.5%) patients had progression, while 3 patients (2.3%) died of NHKS. On univariate analysis, patients who had hypertension (HT) had poorer PFS compared with others (19 ± 12 versus 41 ± 22 months;p = 0.03), whereas plaque formation was associated with better outcome (25 ± 9 versus 54 ± 12 months;p = 0.03). In addition, heavy smoking (≥40 pack-years) had a borderline significance regarding better PFS time (23 ± 24 versus 45 ± 38 months,p = 0.06). On multivariate analysis, none of factors evaluated had any impact on PFS.Conclusions: HT was correlated with poorer outcome among NHKS patients. Patients with plaque formation and ≥40 pack-years of smoking had better PFS than others. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
20. Olfactory bulb volume and olfactory function after radiotherapy in patients with nasopharyngeal cancer.
- Author
-
Veyseller, Bayram, Ozucer, Berke, Degirmenci, Nazan, Gurbuz, Defne, Tambas, Makbule, Altun, Musa, Aksoy, Fadullah, and Ozturan, Orhan
- Subjects
- *
OLFACTORY bulb , *NASOPHARYNX cancer patients , *CANCER radiotherapy , *PHYSIOLOGICAL effects of radiation , *NASOSCOPY , *RADIOLOGISTS - Abstract
Objective Radiotherapy is the primary method of treatment for nasopharyngeal cancer (NPC) and many side effects were reported in patients receiving radiation to this area. This study was conducted to evaluate the long-term effects of radiotherapy following NPC on olfactory bulb (OB) volume and olfactory function. Methods Twenty-four patients with NPC who received radiotherapy at least 12 months ago were recruited. Fourteen healthy subjects with similar demographical characteristics were recruited as the healthy control group. All volunteers were subjected to a nasoendoscopical examination, and abnormalities that could potentially cause olfactory dysfunction were the exclusion criteria from the study. An experienced radiologist segmented the MRI coronal, axial and sagittal slices manually for three-dimensional OB volume measurement in a blinded manner. Olfactory function was assessed using the Connecticut Chemosensory Clinical Research Center (CCCRC) test, and average score (0: worst, 7: best) was calculated as the total CCCRC olfactory score. Results The mean CCCRC score was 5.5 ± 1.1 for the nasopharyngeal cancer patients, whereas the mean score of healthy control group was 6.4 ± 0.4. There was a significant difference in the olfactory scores ( p = 0.003). The mean OB volume in the NPC group was 46.7 ± 12.1 mm 3 . Among the patients with NPC, the cisplatin receiving group had a mean OB volume of 47.2 mm 3 , whereas the cisplatin + docetaxel receiving group had a mean OB volume of 46.5 mm 3 , and they were similar. The MRI measurement of the healthy control group was 58.6 ± 13.8 mm 3 . The OB volumes of the healthy control group were significantly higher ( p < 0.05). Conclusion Radiotherapy following nasopharyngeal cancer results in a diminished OB volume and deteriorated olfactory function. Chemosensory olfactory dysfunction might be a contributing factor to lack of appetite, cancer cachexia and consequent lowered quality of life in NPC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
21. A Decision Support Tool to Optimize Selection of Head and Neck Cancer Patients for Proton Therapy.
- Author
-
Tambas M, van der Laan HP, van der Schaaf A, Steenbakkers RJHM, and Langendijk JA
- Abstract
Selection of head and neck cancer (HNC) patients for proton therapy (PT) using plan comparison (VMAT vs. IMPT) for each patient is labor-intensive. Our aim was to develop a decision support tool to identify patients with high probability to qualify for PT, at a very early stage (immediately after delineation) to avoid delay in treatment initiation. A total of 151 HNC patients were included, of which 106 (70%) patients qualified for PT. Linear regression models for individual OARs were created to predict the D
mean to the OARs for VMAT and IMPT plans. The predictors were OAR volume percentages overlapping with target volumes. Then, actual and predicted plan comparison decisions were compared. Actual and predicted OAR Dmean (VMAT R2 = 0.953, IMPT R2 = 0.975) and NTCP values (VMAT R2 = 0.986, IMPT R2 = 0.992) were highly correlated. The sensitivity, specificity, PPV and NPV of the decision support tool were 64%, 87%, 92% and 51%, respectively. The expected toxicity reduction with IMPT can be predicted using only the delineation data. The probability of qualifying for PT is >90% when the tool indicates a positive outcome for PT. This tool will contribute significantly to a more effective selection of HNC patients for PT at a much earlier stage, reducing treatment delay.- Published
- 2022
- Full Text
- View/download PDF
22. Factors Affecting Survival in Neuroendocrine Tumors: A 15-Year Single Center Experience
- Author
-
Sakin A, Tambas M, Secmeler S, Can O, Arici S, Yasar N, Geredeli C, Demir C, and Cihan S
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Ki-67 Antigen metabolism, Male, Middle Aged, Neoplasm Grading methods, Neoplasm Staging methods, Neuroendocrine Tumors metabolism, Prognosis, Neuroendocrine Tumors mortality, Neuroendocrine Tumors pathology
- Abstract
Background: Neuroendocrine tumors are a heterogeneous group of tumors that can originate from all of the neuroendocrine cells in the body, mostly from the gastrointestinal tract. In addition to early diagnosis, streaming patients into appropriate prognostic groups is an important component of treatment. In this study, we examined the factors that affect survival in patients we followed in our center between 2000-2016. Methods: The demographic data, clinical and pathological features of patients were obtained from their medical files. TNM staging and tumor grading were performed according to AJCC and WHO 2010 classification. SPSS 15.0 for Windows programme was used for statistical analysis. Results: 85 patients (32 male, 53 female) were included into the study. The median age of the patients was 55,7 (27-83) years. Eighty percent of the tumors were of gastroenteropancreatic system, most commonly stomach (27.1%) origin. Nineteen patients (22.4%) died during follow-up. In univariate analysis; age (p<0,001), stage (p=0.002), primary tumor localization (p=0.005), grade (p<0.001), Ki-67 value (p<0.001), number of metastases (p=0.001) and type of surgery (p<0.001) were found to be factors affecting survival. Age (p=0.024) and Ki67 (p <0.001) were the independent prognostic factors for survival in multivariate analysis. For the cut-off value of 6%, Ki-67 had a sensitivity of 83.3% and specifity of 71.4% for survival determination. Conclusion: Ki-67 ratio and age were the most important factors affecting survival in neuroendocrine tumors in our study. Ki-67 ratio has a high sensitivity and specificity for predicting survival, a cut-off value of 6% may be used to predict survival., (Creative Commons Attribution License)
- Published
- 2018
- Full Text
- View/download PDF
23. Do circulating long non-coding RNAs (lncRNAs) (LincRNA-p21, GAS 5, HOTAIR) predict the treatment response in patients with head and neck cancer treated with chemoradiotherapy?
- Author
-
Fayda M, Isin M, Tambas M, Guveli M, Meral R, Altun M, Sahin D, Ozkan G, Sanli Y, Isin H, Ozgur E, and Gezer U
- Subjects
- Area Under Curve, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell therapy, Chemoradiotherapy, Female, Head and Neck Neoplasms mortality, Head and Neck Neoplasms therapy, Humans, Kaplan-Meier Estimate, Male, Middle Aged, ROC Curve, Treatment Outcome, Biomarkers, Tumor blood, Carcinoma, Squamous Cell blood, Head and Neck Neoplasms blood, RNA, Long Noncoding blood
- Abstract
Long non-coding RNAs (lncRNAs) have been shown to be aberrantly expressed in head and neck cancer (HNC). The aim of the present study was to evaluate plasma levels of three lncRNA molecules (lincRNA-p21, GAS5, and HOTAIR) in the treatment response in HNC patients treated with radical chemoradiotherapy (CRT). Forty-one patients with HNC were enrolled in the study. Most of the patients had nasopharyngeal carcinoma (n = 27, 65.9 %) and locally advanced disease. Blood was drawn at baseline and treatment evaluation 4.5 months after therapy. lncRNAs in plasma were measured by semiquantitative PCR. Treatment response was evaluated according to clinical examination, RECIST and PERCIST criteria based on magnetic resonance imaging (MRI), and positron emission tomography with computed tomography (PET/CT) findings. Complete response (CR) rates were 73.2, 36.6, and 50 % for clinical investigation, PET/CT-, or MRI-based response evaluation, respectively. Predictive value of lncRNAs was investigated in patients with CR vs. those with partial response (PR)/progressive disease (PD). We found that post-treatment GAS5 levels in patients with PR/PD were significantly higher compared with patients with CR based on clinical investigation (p = 0.01). Receiver operator characteristic (ROC) analysis showed that at a cutoff value of 0.3 of GAS5, sensitivity and specificity for clinical tumor response were 82 and 77 %, respectively. Interestingly, pretreatment GAS5 levels were significantly increased in patients with PR/PD compared to those with CR upon MRI-based response evaluation (p = 0.042). In contrast to GAS5, pretreatment or post-treatment lincRNA-p21 and HOTAIR levels were not informative for treatment response. Our results suggest that circulating GAS5 could be a biomarker in predicting treatment response in HNC patients.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.